Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Alteplase

Alteplase

Alteplase, also known as tissue plasminogen activator (tPA), is a medication used to treat acute ischemic stroke and myocardial infarction.
It works by dissolving blood clots, thereby improving blood flow to the affected organ.
PubCompare.ai, a leading AI platform, can help researchers optimize the use of Alteplase by providing access to a comprehensive database of research protocols from literature, preprints, and patents.
The platform's AI-driven comparison tools enable users to identify the best protocols and products for their research needs, streamlining the workflow and increasing the efficiency of their studies.
With PubCompare.ai, researchers can rlproduce research protocols with confidence and make informed decisions about the use of Alteplase in their projects.

Most cited protocols related to «Alteplase»

1
Comprehensive Stroke Case Ascertainment Protocol
Cited 28 times
Procedures for complete case capture follow international recommendations for capture–recapture and multiple source ascertainment methods.20 (link) Cases are primarily identified through active pursuit of emergency department and directly admitted stroke patients using validated screening terms.21 (link) The abstractors also routinely canvass intensive care units and hospital floors searching for in-house strokes or those not ascertained through the screening logs. The active surveillance is supplemented by review of hospital passive listings of International Classification of Disease, 9th revision discharge codes for stroke (430–438; excluding 433.x0, 434.x0 [x = 1–9]; 437.0, 437.2, 437.3, 437.4, 437.5, 437.7, 437.8, and 438). County coroner records are screened for causes of sudden stroke death not presenting to the hospital. Several minor changes to case ascertainment procedures were made over the course of the project to maintain efficiency. In 2001, the following diagnostic terms were removed from the active surveillance list: dizziness, falling, imbalance, syncope, and trouble walking. These terms were found to be highly inefficient at identifying strokes, with a positive predict value of ≤1%. Starting January 1, 2001, a sample of Nueces County primary care and cardiology offices, as well as 95% of neurologist offices, were contacted frequently and encouraged to report stroke cases to our project. Abstractors reviewed and abstracted cases not previously screened. The sampling of primary care physicians and cardiologists was subsequently discontinued on January 31, 2004, because during the 3 years of the sampling only 13 ischemic stroke patients were identified exclusively from this method of 1,866 ischemic stroke cases identified in BASIC. Because 74 cases from the sample identified came from neurology offices, we did continue to identify these few stroke cases from neurology offices. From January 31, 2004 to July 31, 2008, only 71 strokes were identified via the neurology office of 1,971 ischemic stroke cases identified. In 2008, we therefore stopped screening neurology offices. From January 1, 2000 through December 1, 2007, BASIC identified cases through active surveillance of both the admissions log and emergency department (ED) log. A review of this methodology in 2007 using complete data from calendar year 2004 suggested that frequent passive ED surveillance in combination with active surveillance of admission logs successfully identifies ≥98% of all ischemic strokes. This new methodology was implemented on December 2, 2007. Finally, we were unable to obtain passive listings of stroke from 1 of the hospital systems for 6 months of 2008. In other 6-month periods, this never amounted to >5 cases. A sensitivity analysis was performed to determine the effects of the changes on incidence rate estimates and ethnic comparisons over time.
Cases are validated by neurologists or a stroke fellowship-trained emergency medicine physician, blinded to subjects’ ethnicity and age, using source documentation. Ischemic stroke diagnosis is based on published international clinical criteria20 (link) that require onset of a focal neurologic deficit following a defined vascular distribution without documented resolution within 24 hours (unless treated with recombinant tissue plasminogen activator) and not explainable by a nonvascular etiology. Imaging is used to discriminate ischemic stroke and hemorrhagic stroke. Because the use of brain MRI has increased greatly in the past 10 years, validators are required to use the original clinical criteria for case validation, so that trend data can be assessed without bias. Therefore, subjects having acute infarction on brain MRI without the clinical deficit described above are validated as no stroke.
Morgenstern L.B., Smith M.A., Sanchez B.N., Brown D.L., Zahuranec D.B., Garcia N., Kerber K.A., Skolarus L.E., Meurer W.J., Burke J.F., Adelman E.E., Baek J, & Lisabeth L.D. (2013). Persistent Ischemic Stroke Disparities despite Declining Incidence in Mexican Americans. Annals of neurology, 74(6), 778-785.
Publication 2013
Alteplase Blood Vessel Brain Brain Infarction Cardiologists Cardiovascular System Cerebrovascular Accident Coroners Diagnosis Ethnicity Fellowships Hemorrhagic Stroke Hypersensitivity Neurologists Patient Discharge Patients Physicians Primary Care Physicians Primary Health Care Stroke, Ischemic Syncope
2
Acute Stroke Intervention Trial (IST-3)
Cited 27 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Acute Cerebrovascular Accidents Alteplase Brain Cerebrovascular Accident Eligibility Determination Ethics Committees, Research Feelings Fibrinolytic Agents Intracranial Hemorrhage Neoplasms Patients Placebos
3
Porcine Blood Clot Formation for Sonothrombolysis
Cited 17 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Alteplase Biological Factors BLOOD citrate phosphate dextrose Citrates Citric Acid Clotrimazole Coagulation, Blood Fibrinolytic Agents Glucose Homo sapiens Microbubbles Pigs Retractions, Clot Serum Susceptibility, Disease Therapies, Investigational Thrombus Tissue Donors Ultrasonography Veins
4
Predictive Value of Discharge Destination for Stroke Outcomes
Cited 14 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Alteplase Angina Pectoris Atrial Fibrillation Cerebrovascular Accident Congestive Heart Failure Diabetes Mellitus Disabled Persons Ethnicity Friend High Blood Pressures Hyperlipidemia Hypersensitivity Patient Discharge Patients Stroke, Ischemic Transient Ischemic Attack Vision
5
Gender Differences in Acute Stroke
Cited 14 times
Between January 2005 and January 2009, 1,055 consecutive patients with acute stroke (i.e., within 7 days after symptom onset) were identified at Soonchunhyang University Hospital. We separated patients according to gender and prospectively analyzed their baseline characteristics, mortality, and functional outcomes at discharge and at 3 months and 1 year after stroke onset. We compared the mean age, time delay from symptom onset to hospital arrival, and risk factors between the genders. The risk factors included past history of hypertension (previous diagnosis, current treatment, or blood pressures of ≥160/95 mmHg in at least two subsequent measurements), diabetes mellitus (previous diagnosis or current treatment with insulin or oral hypoglycemic medications, or a fasting plasma glucose level of ≥126 mg/dL in at least two subsequent measurements), hyperlipidemia (diagnosis or current treatment with lipid-lowering agents, or serum low-density lipoprotein concentration of ≥160 mg/dL), smoking (currently or previously), and potential cardioembolic source.
The existences of previous transient ischemic attack (acute neurological deficit of vascular origin, lasting <24 hours) and stroke (including ischemic or hemorrhagic stroke) were also analyzed. We also investigated compliance with medication for risk factors in those patients with at least one more risk factors. Stroke subtype was classified according to the Trial of Org 10,172 in Acute Stroke Treatment criteria.18 (link)
We analyzed various variables at admission and discharge. At admission, gender differences were assessed in stroke severity according to the National Institutes of Health Stroke Scale (NIHSS), and in the use of intravenous recombinant tissue plasminogen activator (rt-PA). At discharge, the duration of hospital stay, achievement of anticoagulation for high-risk patients of cardioembolic source, stroke severity, functional outcome on the modified Rankin scale (mRS), and mortality during hospitalization were analyzed. The initial neurologic deficits were categorized using the NIHSS into mild (score ≤7), moderate (score >7 and ≤16), and severe (score >16).
Functional outcome as determined by mRS score and mortality were followed up at 3 months and 1 year after stroke onset in the available survivors. The mRS scores were dichotomized into ≤2 (good functional outcome) and >2 (poor outcome). These assessments were made via telephone or face-to-face interview at outpatient clinic.
Univariate and multivariate analyses were performed with SPSS version 15.0 for Windows (SPSS Inc, Chicago, IL, USA). Univariate analysis was performed using the χ2 test for dichotomous variables and the t-test for continuous variables. The level of statistical significance was set at p<0.05. Multivariate analysis was carried out with a logistic regression model. Variables with a probability of p<0.1 in univariate analysis were included in the multivariate analysis. The results of the logistic regressions are presented using 95% confidence intervals (CIs). Other data are presented as mean±SD values except where stated otherwise.
Kim J.S., Lee K.B., Roh H., Ahn M.Y, & Hwang H.W. (2010). Gender Differences in the Functional Recovery after Acute Stroke. Journal of Clinical Neurology (Seoul, Korea), 6(4), 183-188.
Publication 2010
Acute Cerebrovascular Accidents Alteplase Birth Blood Vessel Cerebrovascular Accident Diabetes Mellitus Diagnosis Face Gender Glucose Hemorrhagic Stroke High Blood Pressures Hospitalization Hyperlipidemia Hypoglycemic Agents Hypolipidemic Agents Insulin Low-Density Lipoproteins Patient Discharge Patients Plasma Serum Survivors Transient Ischemic Attack

Most recents protocols related to «Alteplase»

1
Functional Outcome and Intracranial Hemorrhage
The primary outcome measure was functional status at 3 months, evaluated in the hospital's outpatient setting. Because of its ease of use and interpretability, the modified Rankin Scale (mRS) is a widely applied clinical measure of global disability. In particular, it is used to assess recovery from stroke and as a primary end point in randomized clinical trials of stroke treatments. In our study, poor outcome was defined as the occurrence of death or major disability (mRS≥3) (20 (link)).
We also considered symptomatic intracranial hemorrhage (sICH) as a secondary outcome. We defined this hemorrhagic complication usually linked to rt-Pa, through the European Cooperative Acute Stroke Study (ECASS) III criteria, as follows (21 (link)). (1 (link)) Clinical deterioration: an increase of ≥4 points in NIHSS score or that led to death. (2 (link)) Radiographic features: any intracranial hemorrhage on CT/MRI performed at 22–36 h after stroke onset.
Norata D., Lattanzi S., Broggi S., Rocchi C., Bartolini M, & Silvestrini M. (2023). Liver fibrosis-4 score predicts outcome of patients with ischemic stroke undergoing intravenous thrombolysis. Frontiers in Neurology, 14, 1103063.
Full text: Click here
Publication 2023
Acute Cerebrovascular Accidents Alteplase Cerebrovascular Accident Clinical Deterioration Disabled Persons Europeans Hemorrhage Intracranial Hemorrhage Outpatients Radiography
2
Consecutive Patient Stroke Alteplase Study
We conducted this study on consecutive patients to avoid any selection bias. In order to address information bias, two aspects should be considered: the number of lost to follow-up was acceptable (Figure 1); the admission FIB-4 score was calculated only after the 3-month assessment, so the experimenter did not know the score value when assessing the 3-month mRS (primary outcome measure). Based on previous RCTs on Alteplase effectiveness (22 (link)), the minimum number of samples required to achieve a 95% confidence level with a marginal error of 0.05 was 241.
Norata D., Lattanzi S., Broggi S., Rocchi C., Bartolini M, & Silvestrini M. (2023). Liver fibrosis-4 score predicts outcome of patients with ischemic stroke undergoing intravenous thrombolysis. Frontiers in Neurology, 14, 1103063.
Full text: Click here
Publication 2023
Alteplase Patients
3
Pharmacomechanical Thrombus Fragmentation Protocol
Following popliteal access (required with the use of ultrasound guidance) or femoral access with a 10-F sheath under local anaesthesia and strict sterile techniques, RT using a ZelanteDVT catheter or a Solent catheter was performed for pharmacomechanical thrombus fragmentation, suction or aspiration. First, the RT catheter was slowly advanced through the thrombotic segment (only submerged in vessel diameter estimated > 6 mm). For patients without contraindications of thrombolysis, 3 mg of rt-PA [total injected volume of 50 ml] was intraclot injected under the Power Pulse® model. After 20 minutes of dwell time, with the pump unit active during slow catheter passages (3 mm/s to 5 mm/s), runs were performed across the thrombotic segment in a distal-to-proximal or adverse direction under fluoroscopic guidance. Each device activation run lasted at less than 20 seconds with breaks of 30 seconds between the runs to avoid arrhythmia, and the total run times were monitored and kept no more than 240 seconds.
Gong M., Fu G., Liu Z., Zhou Y., Kong J., Zhao B., Lou W., Gu J, & He X. (2023). Rheolytic thrombectomy using an AngioJet ZelanteDVT catheter or a Solent Omni catheter for patients with proximal vein thrombosis. Thrombosis Journal, 21, 25.
Full text: Click here
Publication 2023
Alteplase Blood Vessel Cardiac Arrhythmia Catheters Femur Fibrinolytic Agents Fluoroscopy Local Anesthesia Medical Devices Neoplasm Metastasis Patients Pulse Rate Sterility, Reproductive Suction Drainage Thrombus Ultrasonography
4
Reduced-Dose Alteplase for Residual Thrombus
If residual thrombus (defined as thrombus removal grade ≤ I) was present and did not meet the exclusion criterion of thrombolytic contraindications, a continuous infusion of reduced-dose recombinant tissue plasminogen activator (rt-PA) (Alteplase; Boehringer-Ingelheim, Ingelheim am Rhein, Germany) was delivered subsequently via a multi-side hole catheter (Uni*Fuse, AngioDynamics, Boston Scientific, USA) embedding into the thrombus. Then, 17 mg/20 mg Alteplase was administered at an infusion rate of 0.01 mg/kg per hour following CDT. The maximum rate was less than 1.0 mg/h, and the total doses were less than 50 mg, as noted elsewhere [8 (link)]. CDT was discontinued when at least 80% clot lysis with restoration of flow or a serious complication occurred. Alteplase was administered only when the fibrinogen level was > 1.0 g/L.
Gong M., Fu G., Liu Z., Zhou Y., Kong J., Zhao B., Lou W., Gu J, & He X. (2023). Rheolytic thrombectomy using an AngioJet ZelanteDVT catheter or a Solent Omni catheter for patients with proximal vein thrombosis. Thrombosis Journal, 21, 25.
Full text: Click here
Publication 2023
Alteplase Catheters Clotrimazole Fibrinogen Fibrinolytic Agents rhein Thrombus
5
Intravenous Thrombolysis and Mechanical Thrombectomy for Acute Ischemic Stroke
If patients were eligible for intravenous thrombolysis, 0.9 mg/kg recombinant tissue-type fibrinogen activator (rt-PA) was administered before mechanical thrombectomy according to Chinese guidelines for the endovascular treatment of acute ischemic stroke (15 (link)). The mechanical thrombectomy procedure was performed by two interventional neuroradiologists with 10 years of practice in neurointerventions. The choice of STR or ADAPT was left to the discretion of the operator, usually based on the anatomical location of the thrombus obstruction, preoperative judgment of the etiology and pathogenesis, and the size of the thrombus. All patients were treated with local anesthesia, preferably through the right femoral artery, to establish access. A balloon guide catheter (BGC) was not used in all procedures due to limitations in available device conditions. The ADAPT and SRT techniques have been described previously (16 (link), 17 (link)). Patients received ADAPT using AXS Catalyst-6 (Stryker, USA) as front-line therapy. All stent retriever procedures were performed using the Solitaire FR (Covidien, USA). Meanwhile, intermediate catheters (AXS Catalyst-6) were routinely used. The operator could choose any necessary thrombectomy device and method to obtain an acceptable therapeutic effect if a successful recanalization could not be accomplished after three attempts using SRT or ADAPT.
Fan H., Li Z., Li Y., Tan Y., Mao Z., Liu Q, & Zhu Y. (2023). Comparison of a direct aspiration first pass technique vs. stent retriever thrombectomy for the treatment of acute large vessel occlusion stroke in the anterior circulation with atrial fibrillation. Frontiers in Neurology, 14, 1138993.
Full text: Click here
Publication 2023
Acute Ischemic Stroke Alteplase Catheters Chinese Femoral Artery Fibrinogen Fibrinolytic Agents Histocompatibility Testing Local Anesthesia Medical Devices pathogenesis Patients Stents Therapeutic Effect Therapeutics Thrombectomy Thrombus

Top products related to «Alteplase»

1
Actilyse by Boehringer Ingelheim
Sourced in Germany, France
Actilyse is a laboratory equipment product manufactured by Boehringer Ingelheim. It is a recombinant tissue plasminogen activator (rt-PA) used for the in vitro analysis of fibrinolytic systems.
2
Alteplase by Boehringer Ingelheim
Sourced in Germany
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It functions to dissolve blood clots by activating plasminogen, which then converts fibrin into soluble fragments.
3
Rt pa by Boehringer Ingelheim
Sourced in Germany
Rt-PA is a laboratory equipment product used in research applications. It is a recombinant tissue plasminogen activator, a protein that plays a role in the breakdown of blood clots. The core function of Rt-PA is to facilitate the conversion of plasminogen to plasmin, which is an enzyme involved in the dissolution of fibrin clots.
4
Alteplase by Genentech
Sourced in United States
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It functions by converting plasminogen to plasmin, which then dissolves fibrin clots.
5
Activase by Genentech
Sourced in United States, Cameroon
Activase is a recombinant tissue plasminogen activator (rt-PA) used for the treatment of acute ischemic stroke. It is a laboratory-produced protein that helps dissolve blood clots. Activase is designed to restore blood flow to the brain by breaking down the clot that is blocking the affected blood vessel.
6
Innovin by Siemens
Sourced in Germany, United States, Sweden, United Kingdom
Innovin is a lab equipment product by Siemens. It is a thromboplastin reagent used for the determination of prothrombin time (PT) in plasma samples.
7
Thrombin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Switzerland, Sweden, Ireland, Macao, India, Australia, France, Spain
Thrombin is a serine protease enzyme that plays a crucial role in the blood coagulation process. It is responsible for the conversion of fibrinogen to fibrin, which is the main structural component of blood clots. Thrombin also activates other factors involved in the clotting cascade, promoting the formation and stabilization of blood clots.
8
Human thrombin by Merck Group
Sourced in United States, Germany, China, United Kingdom
Human thrombin is a laboratory product used in research and development applications. It is a serine protease enzyme that plays a crucial role in the blood coagulation process. The core function of human thrombin is to convert fibrinogen into fibrin, which is the essential component in the formation of blood clots.
9
Bovine serum albumin (bsa) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
10
Cathflo activase by Genentech
Sourced in United States
Cathflo Activase is a thrombolytic agent used to restore blood flow through occluded central venous access devices. It contains the active ingredient alteplase, which is a recombinant tissue plasminogen activator that dissolves blood clots.

More about "Alteplase"

Alteplase, also known as tissue plasminogen activator (tPA), is a powerful medication used to treat acute ischemic stroke and myocardial infarction (heart attack).
It works by dissolving blood clots, thereby improving blood flow to the affected organ and preventing further damage.
This medication is marketed under various brand names, including Actilyse, Activase, and Cathflo Activase.
Alteplase is a recombinant form of the human enzyme tissue plasminogen activator (rt-PA).
It is commonly administered intravenously to help break down fibrin, a protein that forms the backbone of blood clots.
By dissolving these clots, Alteplase can restore blood flow to the brain or heart, reducing the risk of permanent damage.
The use of Alteplase in the treatment of acute ischemic stroke and myocardial infarction has been extensively studied in clinical trials, with researchers continuously working to optimize its efficacy and safety.
PubCompare.ai, a leading AI platform, can assist researchers in this endeavor by providing access to a comprehensive database of research protocols from literature, preprints, and patents.
PubCompare.ai's AI-driven comparison tools enable users to identify the best protocols and products for their research needs, streamlining the workflow and increasing the efficiency of their studies.
Researchers can utilize this platform to reproduce research protocols with confidence and make informed decisions about the use of Alteplase in their projects.
In addition to Alteplase, related terms and products such as Innovin (a recombinant tissue factor), Thrombin (a serine protease involved in blood clotting), and Bovine serum albumin (a common protein used in research) may also be relevant to the study and optimization of Alteplase-based therapies.
By leveraging the insights and tools provided by PubCompare.ai, researchers can enhance their understanding and utilization of Alteplase, ultimately leading to improved patient outcomes in the treatment of acute ischemic stroke and myocardial infarction.